FDG PET/CT Evaluation of Pediatric Patients With Yolk Sac Tumor

2019 ◽  
Vol 213 (3) ◽  
pp. 676-682 ◽  
Author(s):  
Wenfang Tang ◽  
Zihao Liu ◽  
Hongliang Fu ◽  
Chao Li ◽  
Hui Wang
2021 ◽  
Vol 47 (1) ◽  
pp. 202-204
Author(s):  
Francisco Javier García-Gómez ◽  
José Luis Villar-Rodríguez ◽  
Carmen Beato-Zambrano ◽  
Pablo Antonio de la Riva-Pérez ◽  
María de la Cinta Calvo-Morón
Keyword(s):  
Fdg Pet ◽  
Yolk Sac ◽  
Pet Ct ◽  
18F Fdg ◽  

2020 ◽  
Vol 45 (6) ◽  
pp. 483-486
Author(s):  
Huimin Sui ◽  
Zhaohui Zhu ◽  
Zheng Li ◽  
Yaping Luo
Keyword(s):  
Fdg Pet ◽  
Yolk Sac ◽  
Pet Ct ◽  
18F Fdg ◽  

2016 ◽  
Vol 41 (7) ◽  
pp. 585-586 ◽  
Author(s):  
Meng Liu ◽  
Guoqian Chen ◽  
Zhanli Fu ◽  
Ziao Li ◽  
Qian Li
Keyword(s):  
Fdg Pet ◽  
Yolk Sac ◽  
Pet Ct ◽  
18F Fdg ◽  

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1112
Author(s):  
Davide Donner ◽  
Paola Feraco ◽  
Linda Meneghello ◽  
Barbara Rombi ◽  
Lorena Picori ◽  
...  

Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood. Despite clinical advances, subsets of these patients continue to suffer high morbidity and mortality rates associated with their disease. Following the European guidelines for 18F-FDG PET and PET-CT imaging in pediatric oncology, the routine use of 18F-FDG PET-CT may be useful for patients affected by rhabdomyosarcoma, in staging, in the evaluation of response to therapy, and for restaging/detection of relapse. The European Pediatric Protocols are very old, and for staging and restaging, they recommend only radionuclide bone scan. The 18F-FDG PET-CT exam is listed as an optional investigation prescribed according to local availability and local protocols in the investigations panel required at the end of the treatment. We present two cases highlighting the usefulness of 18F-FDG PET-CT in managing pediatric patients affected by rhabdomyosarcoma, providing some bibliographic references.


Author(s):  
Mei Tian ◽  
Yasuyoshi Watanabe ◽  
Keon Wook Kang ◽  
Koji Murakami ◽  
Arturo Chiti ◽  
...  

2010 ◽  
Vol 35 (3) ◽  
pp. 192-193 ◽  
Author(s):  
Kenichiro Hamada ◽  
Tetsuho Fujimoto ◽  
Shinsuke Omori ◽  
Makoto Emori ◽  
Susumu Joyama ◽  
...  

2007 ◽  
Vol 26 (2) ◽  
pp. 105-106
Author(s):  
E. Roldán-Valadez ◽  
N. Ortega-López ◽  
I. Vega-González ◽  
G. Valdivieso-Cárdenas ◽  
A. Rumoroso-García ◽  
...  

2013 ◽  
Vol 27 (4) ◽  
pp. 400-405 ◽  
Author(s):  
Ronnie Sebro ◽  
Carina Mari Aparici ◽  
Miguel Hernandez-Pampaloni

2019 ◽  
Vol 67 (1) ◽  
pp. 8-14
Author(s):  
Zehra Pınar KOÇ ◽  
Pelin ÖZCAN KARA ◽  
Yüksel BALCI ◽  
Gülhan ÖREKİCİ ◽  
Rabia BOZDOĞAN ARPACI ◽  
...  

2011 ◽  
Vol 58 (4) ◽  
pp. 67-73
Author(s):  
Strahinja Odalovic ◽  
Dragana Sobic-Saranovic ◽  
Smiljana Pavlovic ◽  
Isidora Grozdic ◽  
Djordjije Saranovic ◽  
...  

The aim of this study was to present preliminary experience with FDG PET/CT in pediatric oncology patients in National PET Center, Clinical Center of Serbia and to asses its impact on management of malignancies in children. 33 FDG PET /CT scans were performed on 30 pediatric patients. PET/CT imaging was performed for staging the disease, assessing therapy efficacy and diagnosing recurrent or metastatic disease. FDG PET/CT changed the stage of the disease in 60.6 % (20/33) of the cases. 14 patients were down-staged after PET/CT, mostly patients with Hodgkin?s disease, were in 7/10 cases PET/CT showed no activity in residual masses. Six scans led to upstage of the disease. In three cases PET/CT did not change the stage of disease, but has showed new distant metastases. In conclusion, FDG PET/CT showed important role in managing pediatric patients with different malignancies and was useful complementary diagnostic tool to conventional imaging methods.


Sign in / Sign up

Export Citation Format

Share Document